AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (97.7%). Net sales break down by treatment area between oncology (35.7%), cardiovascular, renal and metabolic diseases (21.9%), respiratory and autoimmune diseases (16.5%), and other (25.9%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (2.3%).
Net sales are distributed geographically as follows: the United Kingdom (8.7%), Continental Europe (20.9%), Americas (37.5%) and Africa/Asia/Australia (32.9%).
Number of employees : 83 100 people.
2020 2021 Delta Oncology 8 461.00 40.8% 9 487.36 34.9% +12.13%
Cardiovascular, Renal & Metabolism 5 533.57 26.7% 5 831.44 21.4% +5.38%
Respiratory & Immunology 4 177.47 20.1% 4 387.39 16.1% +5.03%
COVID-19 - - 2 909.90 10.7% -
Rare Disease - - 2 232.23 8.2% -
Other Medicines 2 017.38 9.7% 1 721.07 6.3% -14.69%
Collaboration 566.93 2.7% 636.95 2.3% +12.35%
GBP in Million
2020 2021 Delta United States 6 983.25 33.6% 8 759.52 32.2% +25.44%
China 4 168.11 20.1% 4 364.13 16% +4.7%
Japan 2 001.79 9.6% 2 468.55 9.1% +23.32%
United Kingdom 1 357.66 6.5% 2 359.48 8.7% +73.79%
Other Asia, Africa and Australasia 1 196.24 5.8% 1 729.80 6.4% +44.6%
Sweden 800.09 3.9% 1 688.35 6.2% +111.02%
Other Rest of Europe 1 084.72 5.2% 1 417.14 5.2% +30.65%
Germany 730.69 3.5% 1 080.49 4% +47.87%
Other Americas 593.44 2.9% 874.72 3.2% +47.4%
France 509.22 2.5% 665.31 2.4% +30.65%
Canada 464.77 2.2% 561.33 2.1% +20.78%
Spain 310.37 1.5% 420.27 1.5% +35.41%
Italy 336.10 1.6% 419.54 1.5% +24.83%
Australia 219.91 1.1% 397.73 1.5% +80.86%
GBP in Million
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
1,549,489,389
1,493,140,483
96.4%
0
0.0%
96.4%
Shareholders AstraZeneca PLC (GB0009895292) AstraZeneca PLC (US)
Name Equities % BlackRock Investment Management (UK) Ltd. 87,816,365
5.67% Wellington Management Co. LLP 64,146,178
4.14% Investor AB (Investment Company) 51,587,810
3.33% The Vanguard Group, Inc. 48,125,000
3.11% Capital Research & Management Co. (World Investors) 46,132,337
2.98% Norges Bank Investment Management 30,921,000
2.00% BlackRock Fund Advisors 27,770,415
1.79% BlackRock Advisors (UK) Ltd. 21,488,979
1.39% GQG Partners LLC 15,351,000
0.99% SSgA Funds Management, Inc. 13,564,000
0.88%
Name Equities % Investor AB (Investment Company) 190,171,620
6.14% T. Rowe Price Associates, Inc. (Investment Management) 94,229,869
3.04% Wellington Management Co. LLP 46,691,035
1.51% PRIMECAP Management Co. 46,317,880
1.49% Capital Research & Management Co. (International Investors) 36,993,664
1.19% Fisher Asset Management LLC 20,842,845
0.67% GQG Partners LLC 18,280,681
0.59% Capital Research & Management Co. 14,965,800
0.48% Franklin Advisers, Inc. 13,210,362
0.43% Regents of the University of California 10,965,024
0.35%
Name Equities % Valuation
ASTRAZENECA PHARMA INDIA LIMITED (506820)
18,750,000
75.0%
641,912,438 USD
DIZAL JIANGSU PHARMACEUTICAL CO. LTD.
108,923,023
29.8%
435,086,480 USD
ADC THERAPEUTICS SA (ADCT)
4,011,215
5.22%
31,889,159 USD
CIRCASSIA GROUP PLC (CIR)
71,059,999
16.9%
29,773,429 USD
INNATE PHARMA (IPH)
7,485,500
9.39%
20,065,107 USD
PIERIS PHARMACEUTICALS, INC. (PIRS)
3,584,230
4.97%
6,702,510 USD
ENTASIS THERAPEUTICS HOLDINGS, INC.
2,164,855
4.52%
4,762,681 USD
PHASEBIO PHARMACEUTICALS, INC. (PHAS)
3,004,554
6.17%
1,802,732 USD
ARIDIS PHARMACEUTICALS, INC. (ARDS)
884,956
5.00%
973,452 USD
- Main Market
- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Nasdaq 100, NASDAQ OMX Nordic 120, OMX Nordic 40, OMX Stockholm 30, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
- Bloomberg Code :
AZN:LN
- Reuters Code :
AZN.L
- Datastream Code :
Company contact information
Chasing green goals, corporations push car fleet managers toward EVs
Sector Other Pharmaceuticals
Connections : AstraZeneca PLC